Eisai to cut 900 jobs ahead of Aricept patent loss
pharmafile | March 7, 2011 | News story | Sales and Marketing | Aricept, Eisai, donepezil, generics, job cuts
Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it gears up to face generic competition for Aricept.
The Alzheimer’s drug, developed in partnership with Pfizer, is a key part of its pharma portfolio but will lose exclusivity in the US by the end of the year.
Aricept (donepezil) made the Japanese pharma firm 322.8 billion yen ($3.89 billion) in revenue for 2010, accounting for about 40% of its total sales.
Meanwhile, Eisai’s novel cancer drug Halaven delivered promising phase III results.
Halaven, which demonstrated an increase in overall survival for late stage metastatic breast cancer patients, could help the company offset the loss of Aricept and gain a strong market position in a hard to treat cancer.
Ben Adams
Related Content
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …

Eisai and EcoNaviSta enter dementia collaboration
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating …

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …






